Palvella Therapeutics

Rare disease biopharmaceutical company.

Launch date

2015

Employees

Market cap

Enterprise valuation

$225m (Public information from Jan 2023)

Radnor Township Pennsylvania (HQ)

Date	Investors	Amount	Round
Aug 2017	BioAdvance 13 Ventures	N/A	-
Jun 2018	N/A	$4.4m	Early VC
Dec 2018*	Ligand Pharmaceuticals	$10.0m	Early VC
May 2020*	Samsara BioCapital CAM Capital	$45.0m	Series C
Jan 2023*	BioAdvance BVF Partners Agent Capital Gore Range Capital Samsara BioCapital Nolan Capital Petrichor	$9.7m Valuation: $225m	Series D
Jul 2024*	N/A	N/A	IPO
Jul 2024*	Dafna Capital Management BioAdvance BVF Partners Gore Range Capital Ligand Pharmaceuticals Samsara BioCapital CAM Capital Nantahala Capital Management Petrichor Blue Owl Capital Integrated Finance Frazier Life Sciences ADAR1 Capital Management	$78.9m	Post IPO Equity
Total Funding		$69.1m

Tech stackLearn more about the technologies and tools that this company uses.

ACQUISITION by Palvella Therapeutics Jul 2024

Recent News about Palvella Therapeutics